The aim of this study was to provide a simple, reproducible, and point-of-care assessment of peri-prosthetic aortic regurgitation (periAR) during transcatheter aortic valve implantation (TAVI) and to decipher the impact of this peri-procedural parameter on outcome.
Background
Because periAR after TAVI might be associated with adverse outcome, precise quantification of periAR is of paramount importance but remains technically challenging.
Methods
The severity of periAR was prospectively evaluated in 146 patients treated with the Medtronic CoreValve (Minneapolis, Minnesota) prosthesis by echocardiography, angiography, and measurement of the aortic regurgitation (AR) index, which is calculated as ratio of the gradient between diastolic blood pressure (DBP) and left ventricular end-diastolic pressure (LVEDP) to systolic blood pressure (SBP): [(DBP Ϫ LVEDP)/SBP] ϫ 100.
Results
After TAVI, 53 patients (36.3%) showed no signs of periAR and 71 patients (48.6%) showed only mild periAR, whereas 18 patients (12.3%) and 4 patients (2.7%) suffered from moderate and severe periAR, respectively. The AR index decreased stepwise from 31.7 Ϯ 10.4 in patients without periAR, to 28.0 Ϯ 8.5 with mild periAR, 19.6 Ϯ 7.6 with moderate periAR, and 7.6 Ϯ 2.6 with severe periAR (p Ͻ 0.001), respectively. Patients with AR index Ͻ25 had a significantly increased 1-year mortality risk compared with patients with AR index Ն25 (46.0% vs. 16.7%; p Ͻ 0.001). The AR index provided additional prognostic information beyond the echocardiographically assessed severity of periAR and independently predicted 1-year mortality (hazard ratio: 2.9, 95% confidence interval: 1.3 to 6.4; p ϭ 0.009).
Conclusions
The assessment of the AR index allows a precise judgment of periAR, independently predicts 1-year mortality after TAVI, and provides additional prognostic information that is complementary to the echocardiographically assessed severity of periAR. Transcatheter aortic valve implantation (TAVI) has evolved as an alternative to surgical aortic valve replacement in patients with symptomatic severe aortic stenosis who are considered to be at very high or prohibitive operative risk (1) . Although the PARTNER (Placement of AoRTic TraNscathetER Valve) trial recently demonstrated that TAVI is associated with similar mortality at 30 days and 1 year in surgical high-risk patients compared with surgical aortic valve replacement, a number of TAVI-associated drawbacks have been identified, including a higher incidence of peri-prosthetic aortic regurgitation (periAR). Recently published studies report an incidence of moderate/severe periAR after TAVI of approximately 15% to 20% (1) (2) (3) (4) (5) (6) .
Precise echocardiographic or angiographic quantification of periAR in TAVI patients remains challenging, especially during implantation, despite the recently published Valve Academic Research Consortium (VARC) criteria (7, 8) .
However, the importance of accurately defining the severity of periAR immediately after valve implantation (within the catheterization laboratory) is paramount, because increasing evidence suggests that periAR has a significant impact on short-and long-term outcome after TAVI (2, 6) . Thus, an objective parameter to assess directly and precisely the severity of periAR in TAVI patients during the procedure is essential to take effective countermeasures such as post-dilation, snaring, or valve-in-valve implantation to decrease periAR.
The aim of our study was to provide a simple, reproducible, and point-of-care assessment of periAR during TAVI and to decipher the impact of the aortic regurgitation (AR) index, defined as the ratio of the gradient between diastolic blood pressure (DBP) in the aorta and left ventricular end-diastolic pressure (LVEDP) to systolic blood pressure (SBP), on survival after TAVI.
Methods
Patient population. Patients (N ϭ 146) underwent TAVI with use of the third-generation CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) and were included into this prospective study after written informed consent.
Before TAVI, annulus dimension was evaluated with 3-dimensional transesophageal echocardiography (TEE), angiography of the aortic root, and multi-slice computed tomography. The TAVI was performed with biplane fluoroscopy under local anesthesia in combination with a sedative/analgesic treatment. Intraprocedural TEE was not routinely performed, and the procedure was predominantly guided by angiographic control.
The primary endpoint of this study was all-cause mortality at 1 year. Clinical outcomes and the degree of periAR were defined according to VARC criteria (7) . Information about the cause of death was obtained from the treating hospital, referring cardiologist, or general practitioner. The study was approved by the local ethics committee of the University of Bonn. Echocardiographic assessment of periAR. The occurrence and degree of periAR was assessed by angiography immediately after TAVI and by transthoracic echocardiography or TEE until Day 3 after TAVI according to the recently published VARC criteria (7) . The evaluation of periAR was performed by a blinded echocardiographer who did not attend the procedure. Hemodynamic assessment of periAR. In all patients, the pressure in the left ventricle and in the ascending aorta was determined simultaneously after the procedure. The gradient between DBP in the aorta and LVEDP was calculated over several cardiac cycles to evaluate the severity of periAR (Fig. 1) . To adjust the gradient for the respective SBP of the patient, we calculated the dimensionless AR index according to the following formula: [(DBP Ϫ LVEDP)/SBP] ϫ 100. For our analysis, we used the final calculation of the AR index just before the end of the TAVI procedure (mostly within 10 to 15 min after valve deployment). Statistical analysis. Data are presented as mean Ϯ SD if normally distributed or as median and interquartile range if not normally distributed. Continuous variables were tested for normal distribution with the use of the Kolmogorov-Smirnov test. Categorical variables are given as frequencies and percentages. For continuous variables, a Student t test was performed for comparison between 2 groups. When comparing more than 2 groups, analysis of variance or the Kruskal-Wallis test was used. For categorical variables, the chi-square or Fisher exact test were used for further analysis.
The cutoff value of the AR index for the prediction of all-cause mortality at 1 year was determined in receiveroperating characteristic curve analysis as maximum sum of sensitivity and specificity to minimize both the number Values are mean Ϯ SD n (%). AKI ϭ acute kidney injury; AR ϭ aortic regurgitation; CABG ϭ coronary artery bypass grafting; COPD ϭ chronic obstructive pulmonary disease; LVEF ϭ left ventricular ejection fraction; EuroSCORE ϭ European System for Cardiac Operative Risk Evaluation score; LCC ϭ left-coronary cusp; MI ϭ myocardial infarction; NCC ϭ non-coronary cusp; NT-proBNP ϭ N-terminal pro-hormone brain natriuretic peptide; NYHA ϭ New York Heart Association; PCI ϭ percutaneous coronary intervention; periAR ϭ peri-prosthetic aortic regurgitation; STS ϭ Society of Thoracic Surgeons. published VARC criteria for the assessment of the severity of periAR (7), the echocardiographic grading was used for further analysis. For the comparison of baseline characteristics, patients were divided into 2 groups according to the occurrence of echocardiographically confirmed periAR (none/mild vs. moderate/severe) after TAVI. The latter was considered clinically relevant. Patients with moderate/severe periAR were more often male (77.3% vs. 42.7%; p ϭ 0.003) and taller (173.8 Ϯ 10.1 cm vs. 166.0 Ϯ 8.1 cm; p Ͻ 0.001) than patients with none/mild periAR ( Table 1 ). The mean aortic annulus diameter was significantly larger (25.1 Ϯ 2.4 mm vs. 23.2 Ϯ 1.9 mm; p Ͻ 0.001) and the cover index was significantly lower (10.1 Ϯ 6.1% vs. 16.0 Ϯ 4.6%; p Ͻ 0.001) in patients suffering from moderate/severe periAR, compared with patients with none/mild periAR ( Table 2) . Hemodynamic assessment of periAR. Simultaneous measurement of the left ventricular and aortic pressure showed a stepwise decrease of the gradient between LVEDP and the DBP in the aorta with increasing degree of periAR (p Ͻ 0.001) immediately after valve implantation ( Table 2 ). In patients with none/mild periAR, the LVEDP decreased from 16.6 Ϯ 5.0 mm Hg before to 13.6 Ϯ 6.8 mm Hg (p ϭ 0.001) after the procedure, whereas the LVEDP increased during the TAVI procedure in patients with post-interventional moderate/severe periAR from 14.9 Ϯ 5.3 mm Hg to 18.3 Ϯ 6.2 mm Hg (p Ͻ 0.001).
The AR index decreased in parallel with increasing severity of periAR, from 31.7 Ϯ 10.4 in patients without periAR to 28.0 Ϯ 8.5 in patients with mild periAR, 19.6 Ϯ 7.6 in patients with moderate periAR, and 7.6 Ϯ 2.6 in patients with severe periAR (p Ͻ 0.001) (Fig. 2) . Clinical outcomes after TAVI. Of 146 patients, 10 (6.8%) died within the first 30 days after TAVI, and 39 (26.7%) died during follow-up of up to 1 year. The echocardiographically assessed severity of periAR was significantly associated with 30-day and 1-year mortality after TAVI (p ϭ 0.001 and p Ͻ 0.001, respectively) ( Table 3 ). In patients with none/mild periAR, a 1-year mortality of 20.2% (25 of 124) was observed, compared with 63.6% (14 of 22) in patients with moderate/severe periAR (p Ͻ 0.001) (Fig. 3A) .
In univariate regression analysis, the occurrence of moderate/severe periAR was associated with an increased risk for 1-year mortality (hazard ratio [HR]: 3.9, 95% confidence interval [CI]: 2.0 to 7.5; p Ͻ 0.001 after TAVI (Table 4) . The AR index and outcome. The optimal AR index cutoff value for the prediction of mortality at 1 year was calculated by receiver-operating characteristic curve analysis: Patients with AR index Ͻ25 had a significantly increased 1-year mortality risk, compared with patients with AR index Ն25 (46.0% vs. 16.7%: p Ͻ 0.001) (Fig. 3B) . In multivariate regression analysis, the AR index independently predicted 1-year mortality (HR: 2.9, 95% CI: 1.3 to 6.4; p ϭ 0.009)-even after adjustment for the severity of periAR.
Because both parameters-severity of periAR and the hemodynamic AR index-impact outcome of TAVI patients and are readily assessable immediately after valve Hemodynamic Variables, AR Index, and Laboratory Parameters at 48 h After TAVI According to the Degree of PeriAR Table 1 .
Figure 2 AR Index According to Degree of PeriAR
The AR index according to the degree of periAR as assessed by echocardiography after transcatheter aortic valve implantation. Abbreviations as in Figure 1 .
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Aortic Regurgitation Index Predicts Outcome After TAVI implantation in the catheterization laboratory, we stratified our study population accordingly (Fig. 4) . The 1-year mortality risk, attributed to the severity of periAR (none/ mild vs. moderate/severe), could be further stratified by the AR index (p Ͻ 0.001). In patients with none/mild periAR, an AR index Ն25 (n ϭ 91) was related to a 1-year mortality rate of 15.4%, whereas an AR index Ͻ25 (n ϭ 33) was associated with a more-than 2-fold higher 1-year mortality rate of 33.3%. Patients with moderate/severe periAR and AR index Ͻ25 (n ϭ 17) had the worst outcome, with a 1-year mortality rate of 70.6%.
Discussion
In this prospective study of 146 TAVI patients who underwent TAVI with the Medtronic CoreValve prosthesis, the degree of periAR after TAVI, quantified by echocardiography, was related to a significant increase in the risk of short-and long-term mortality. The AR index, which was calculated as the ratio of the end-diastolic gradient across the valve prosthesis to systolic blood pressure, decreased stepwise in parallel with increasing severity of periAR and allowed a precise judgment of the degree of periAR. This hemodynamic parameter also strongly predicted 1-year mortality after TAVI-independent of the degree of periAR-and provided additional prognostic information that was complementary to the echocardiographically assessed severity of periAR. Predictors of periAR after TAVI. Heavily calcified cusps, misplacement of the prosthesis, and/or annulus-prosthesis-size mismatch can cause periAR (Fig. 5) . We confirmed that annulus diameter and prosthesis implantation depth are associated with the occurrence of moderate/severe periAR after TAVI (3) (4) (5) (6) 9) . Furthermore, the cover index, which is a surrogate for prosthesis/annulus incongruence, was significantly lower in patients with moderate/severe periAR in our study cohort (4). This significant relationship between low cover index and AR suggests that a certain degree of prosthesis oversizing is needed to ensure an adequate adaptation of the prosthesis to the aortic annulus. Conversely, recent data indicated that greater oversizing of the valve with respect to the aortic annulus was not associated Clinical Outcomes According to the Occurrence of Moderate/Severe PeriAR After TAVI with lesser incidence and severity of periAR, suggesting that other mechanisms such as the degree of valve calcification or leaflet-commissural deformation might have additional impact (5). These observations would explain at least in part why in some of our patients the degree of periAR could not be improved, despite appropriate implantation depth and post-dilation maneuvers. PeriAR and outcome after TAVI. Recent analyses suggested the importance of post-procedural periAR for shortand long-term outcome (2, 6) . In our analysis, moderate/ severe periAR, which occurred in 15% of our patients, was strongly related to both 30-day and 1-year mortality. In addition, the AR index was a strong and independent predictor of 1-year mortality risk-even after adjustment for the severity of periAR-indicating the independent relevance of objectively assessed hemodynamic changes in the long run.
Our data demonstrate that all measures must be taken to avoid moderate/severe periAR. Thus, effective countermeasures to decrease periAR might increase survival. Balloon valvuloplasty is usually the first step to optimize moderate/severe periAR in patients with appropriate implantation depth of the prosthesis. Correction of a deep implantation depth of the prosthesis can be overcome by the use of snare catheters, whereas for misplaced or embolized valves, the implantation of a second prosthesis in "valve-invalve" technique is the ultimate bailout option (3). Quantification of periAR after TAVI. The precise quantification of the degree of periAR remains challenging, despite the recently suggested VARC criteria (3) (4) (5) (6) (7) (8) . Most semi-quantitative Doppler parameters of AR severity are best applied in central regurgitation jets and, hence, might not be ideal to quantify the frequently diffuse and eccentric 
